THERACRYF PLC
Get an alert when THERACRYF PLC files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2025-03-31
Confirmation statement due
2026-11-01 (in 6mo)
Last made up 2025-10-18
Watchouts
None on the register
Cash
£4M
+105.3% vs 2024
Net assets
£6M
+155% vs 2024
Employees
9
0% vs 2024
Profit before tax
-£2M
+41.5% vs 2024
Name history
Renamed 2 times since incorporation
- THERACRYF PLC 2024-04-25 → present
- EVGEN PHARMA PLC 2015-10-14 → 2024-04-25
- EVGEN PHARMA LIMITED 2014-10-02 → 2015-10-14
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2025-03-31
| Metric | Trend | 2024-03-31 | 2025-03-31 |
|---|---|---|---|
| Turnover | £396,000 | £0 | |
| Operating profit | -£3,566,000 | -£2,124,000 | |
| Profit before tax | -£3,566,000 | -£2,085,000 | |
| Net profit | -£3,137,000 | -£1,941,000 | |
| Cash | £2,004,000 | £4,114,000 | |
| Total assets less current liabilities | £2,340,000 | £5,968,000 | |
| Net assets | £2,341,000 | £5,969,000 | |
| Equity | £2,341,000 | £5,969,000 | |
| Average employees | 9 | 9 | |
| Wages | £755,000 | £563,000 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2024-03-31 | 2025-03-31 |
|---|---|---|---|
| Operating margin | -900.5% | — | |
| Net margin | -792.2% | — | |
| Return on capital employed | -152.4% | -35.6% | |
| Gearing (liabilities / total assets) | 23.5% | 21.8% | |
| Current ratio | 4.19x | 3.11x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- UK-adopted International Accounting Standards
- Reporting scope
- Consolidated group
- Auditor
- RSM UK Audit LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Directors estimate that the cash held by the Group together with known receivables will be sufficient to support the planned level of activities to the fourth quarter of 2026. They have therefore prepared the financial statements on a going concern basis.”
Group structure
- THERACRYF PLC · parent
- TheraCryf Pharma Ltd 100%
- Chronos Therapeutics Ltd 100%
Significant events
- “Acquisition and full integration of Chronos Therapeutics Ltd, with Chronos becoming a wholly owned subsidiary.”
- “Sudden passing of Chair, Dr Sue Foden in November 2024.”
- “Seasoned, listed company Biotech executive Dr Alastair Smith welcomed as new Chair in February 2025.”
- “Post period: Edward (Ed) Wardle joins Board as non-executive director nominated by new major investor Northern Standard Ltd.”
- “Our acquisition of Chronos Therapeutics in April 2024 expanded our pre-clinical pipeline with two potentially high value assets to treat brain disorders.”
- “On 05 April 2024, the Group acquired the entire share capital of Chronos Therapeutics Limited for a total combined consideration of £1,983k.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
6 active · 10 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| PRISM COSEC LIMITED | Corporate Secretary | 2018-08-20 | — | — |
| BARGE, Alan John, Dr | Director | 2015-10-21 | Sep 1957 | British |
| HAENNINEN, Toni Markus Antero | Director | 2024-01-01 | Dec 1977 | Finnish |
| JONES, Huw, Dr | Director | 2020-10-01 | Nov 1959 | British |
| SMITH, David Alastair Maclaughlin, Dr | Director | 2025-02-19 | Oct 1966 | British |
| WARDLE, Edward James Norman | Director | 2025-05-01 | May 1991 | British |
Show 10 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| DAVID VENUS & COMPANY LLP | Corporate Secretary | 2015-06-29 | 2018-08-20 |
| BRADSHAW, John | Director | 2014-11-21 | 2017-03-01 |
| CLARE, Barry | Director | 2014-10-02 | 2023-09-22 |
| CLEMENT-DAVIES, Susan Elizabeth | Director | 2018-11-08 | 2023-12-31 |
| D'ABBADIE, Marc Francois | Director | 2014-11-21 | 2018-11-08 |
| FODEN, Susan Elizabeth, Dr | Director | 2014-11-21 | 2024-11-01 |
| FRANKLIN, Stephen, Dr | Director | 2014-10-02 | 2020-04-30 |
| JONES, Huw, Dr | Director | 2020-10-30 | 2020-10-30 |
| MOULSON, Richard Anthony | Director | 2017-03-01 | 2023-07-20 |
| WYATT, Mark | Director | 2014-11-21 | 2017-03-31 |
Ownership
Persons with significant control
Filing timeline
Last 20 of 106 total filings
Material constitutional events — rename, articles re-file, resolution
- 2025-08-14 RESOLUTIONS Resolution
- 2024-07-25 RESOLUTIONS Resolution
- 2024-04-25 CERTNM Certificate change of name company PDF
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-10-21 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-08-29 | AA | accounts | Accounts with accounts type group | |
| 2025-08-14 | RESOLUTIONS | resolution | Resolution | |
| 2025-05-07 | SH01 | capital | Capital allotment shares | |
| 2025-05-07 | AP01 | officers | Appoint person director company with name date | |
| 2025-04-16 | SH01 | capital | Capital allotment shares | |
| 2025-03-05 | AP01 | officers | Appoint person director company with name date | |
| 2024-12-15 | SH01 | capital | Capital allotment shares | |
| 2024-11-06 | TM01 | officers | Termination director company with name termination date | |
| 2024-10-31 | CH01 | officers | Change person director company with change date | |
| 2024-10-31 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-10-29 | SH01 | capital | Capital allotment shares | |
| 2024-10-29 | CH01 | officers | Change person director company with change date | |
| 2024-07-25 | RESOLUTIONS | resolution | Resolution | |
| 2024-07-15 | AA | accounts | Accounts with accounts type group | |
| 2024-04-25 | CERTNM | change-of-name | Certificate change of name company | |
| 2024-01-01 | AP01 | officers | Appoint person director company with name date | |
| 2024-01-01 | TM01 | officers | Termination director company with name termination date | |
| 2023-10-16 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-10-16 | CH01 | officers | Change person director company with change date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 5
- Capital events
- 4
- Officers appointed
- 1
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2024 → FY2025 · period ending 2025-03-31 vs 2024-03-31
-
Turnover
-100%
£396,000 £0
-
Cash
+105.3%
£2,004,000 £4,114,000
-
Net assets
+155%
£2,341,000 £5,969,000
-
Employees
0%
9 9
-
Operating profit
+40.4%
-£3,566,000 -£2,124,000
-
Profit before tax
+41.5%
-£3,566,000 -£2,085,000
-
Wages
-25.4%
£755,000 £563,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers